Collaborations

School of Pharmacy, University College London
Kuecept Ltd has strategically worked in partnership with the School of Pharmacy, University College London since our inception, primarily in the field of research, development and commercialisation of new drug delivery technologies to address unmet market needs in key therapeutic areas. Currently we are applying several of these drug delivery technologies to help facilitate our client’s own innovation pipelines as well as providing product differentiation and Life Cycle Management for high value commercialised products.

Institute of Life Sciences, Swansea
Kuecept Ltd was the first company to sign up as an Affiliate of the Institute of Life Science (ILS), which is the research arm of Swansea University. The Institute is a £52 million purpose-built facility strategically located between the College of Medicine and Singleton Hospital, part of the Abertawe Bro Morgannwg University Health Board. Our ongoing collaborative research is focussed on the design and development of improved performance medications in the field of human reproductive biology and hormone therapy.

Lena Nanoceutics
Kuecept Ltd and Lena Nanoceutics have worked together over the past 4 years, both as business development partners and in collaborative research. The collaboration has enabled Kuecept to to integratd the patented Lena-Nano technology into its own potfolio of drug delivery initiatives and allows for rapid and scalable production of crystalline drug nano-suspensions and redispersable nano-powders . The technology can be applied to a varied of dosage forms and routes of administration, including oral and parenteral. For more information on the technology, please click here.

Agenda 1
The Kuecept - Agenda 1 relationship was established for one simple reason: synergy. Agenda 1 provides high-value and cost effective cGMP analytical services to the pharmaceutical, biotech and healthcare and through our Lab time-share partnership enables Kuecept to access extra resource at short notice and when demands exceed our own internal capacities. In addition, Kuecept and Agenda1 have co-developed the exclusive Solent™ Rapid Formulation Screening platform, which to date has been used by over 50 organisations globally on over 120 test compounds. For more information on Agenda 1, please click here.